Company profile for Pilatus Biosciences

NEW Drugs in Dev.: 1
PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Pilatus Biosciences is at the forefront of discovering and developing first-in-class antibodies and bifunctional proteins targeting metabolic checkpoints. Their innovative approach aims to reprogram the immune microenvironment to enhance the body’s ability to combat cancer. By targeting key metabolic pathways, Pilatus seeks to develop novel therapies that can improve cancer treatment outcomes and potentially revolutionize im...
Pilatus Biosciences is at the forefront of discovering and developing first-in-class antibodies and bifunctional proteins targeting metabolic checkpoints. Their innovative approach aims to reprogram the immune microenvironment to enhance the body’s ability to combat cancer. By targeting key metabolic pathways, Pilatus seeks to develop novel therapies that can improve cancer treatment outcomes and potentially revolutionize immuno-oncology.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Switzerland
Address
Address
Superlab Suisse Lausanne, Lab 5 Route de la Corniche 6 1066 Epalinges
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251212767192/en/Pilatus-Biosciences-Announces-FDA-Clearance-of-IND-Application-for-PLT012-a-First-in-Class-Anti-CD36-Metabolic-Checkpoint-Antibody-in-Solid-Tumors

BUSINESSWIRE
15 Dec 2025

https://www.prnewswire.com/news-releases/pilatus-biosciences-to-present-new-preclinical-data-highlighting-plt012s-ability-to-induce-durable-anti-tumor-immunity-through-immunometabolic-reprogramming-of-the-tumor-microenvironment-at-sitc-2025-annual-meeting-302599643.html

PR NEWSWIRE
30 Oct 2025

https://www.businesswire.com/news/home/20251014693867/en/Pilatus-Biosciences-Announces-Issuance-of-Foundational-Global-Patent-Covering-Novel-CD36-Targeted-Immunotherapy

BUSINESSWIRE
14 Oct 2025

https://www.businesswire.com/news/home/20250813741707/en/Pilatus-Biosciences-Announces-Clinical-Trial-Collaboration-with-Roche-to-Evaluate-PLT012-in-First-in-Human-Study-in-Hepatocellular-Carcinoma

BUSINESSWIRE
13 Aug 2025

https://www.businesswire.com/news/home/20250429248765/en/Pilatus-Biosciences-Publishes-Preclinical-Data-in-Cancer-Discovery-on-PLT012-First-in-Class-CD36-Targeting-Antibody-for-Liver-Cancer

BUSINESSWIRE
29 Apr 2025

https://www.prnewswire.com/news-releases/pilatus-biosciences-to-present-research-on-plt012-at-aacr-2025-302428942.html

PR NEWSWIRE
15 Apr 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty